211 related articles for article (PubMed ID: 8247036)
1. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer.
Arriagada R; Le Chevalier T; Pignon JP; Rivière A; Monnet I; Chomy P; Tuchais C; Tarayre M; Ruffié P
N Engl J Med; 1993 Dec; 329(25):1848-52. PubMed ID: 8247036
[TBL] [Abstract][Full Text] [Related]
2. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
Turrisi AT; Kim K; Blum R; Sause WT; Livingston RB; Komaki R; Wagner H; Aisner S; Johnson DH
N Engl J Med; 1999 Jan; 340(4):265-71. PubMed ID: 9920950
[TBL] [Abstract][Full Text] [Related]
3. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
Spiro SG; James LE; Rudd RM; Trask CW; Tobias JS; Snee M; Gilligan D; Murray PA; Ruiz de Elvira MC; O'Donnell KM; Gower NH; Harper PG; Hackshaw AK;
J Clin Oncol; 2006 Aug; 24(24):3823-30. PubMed ID: 16921033
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
5. Limited small cell lung cancer: possible prognostic impact of initial chemotherapy doses.
Arriagada R; de The H; Le Chevalier T; Thomas F; Ruffie P; de Cremoux H; Martin M; Duroux P; Dewar J; Sancho-Garnier H
Bull Cancer; 1989; 76(6):604-15. PubMed ID: 2550102
[TBL] [Abstract][Full Text] [Related]
6. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
7. Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience.
Shepherd FA; Ginsberg RJ; Feld R; Evans WK; Johansen E
J Thorac Cardiovasc Surg; 1991 Mar; 101(3):385-93. PubMed ID: 1847981
[TBL] [Abstract][Full Text] [Related]
8. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
Keller SM; Adak S; Wagner H; Herskovic A; Komaki R; Brooks BJ; Perry MC; Livingston RB; Johnson DH
N Engl J Med; 2000 Oct; 343(17):1217-22. PubMed ID: 11071672
[TBL] [Abstract][Full Text] [Related]
10. [Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy].
Payne DG; Murray N; Warde P
Bull Cancer; 1994 Feb; 81(2):119-28. PubMed ID: 7894117
[TBL] [Abstract][Full Text] [Related]
11. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. "Petites Cellules" Group.
Urban T; Chastang C; Lebas FX; Duhamel JP; Adam G; Darse J; Bréchot JM; Lebeau B
Cancer; 1999 Dec; 86(11):2238-45. PubMed ID: 10590363
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
Schild SE; Bonner JA; Shanahan TG; Brooks BJ; Marks RS; Geyer SM; Hillman SL; Farr GH; Tazelaar HD; Krook JE; Geoffroy FJ; Salim M; Arusell RM; Mailliard JA; Schaefer PL; Jett JR
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):943-51. PubMed ID: 15234027
[TBL] [Abstract][Full Text] [Related]
13. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
Shepherd FA; Evans WK; MacCormick R; Feld R; Yau JC
Cancer Treat Rep; 1987 Oct; 71(10):941-4. PubMed ID: 2820571
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.
Dillman RO; Seagren SL; Propert KJ; Guerra J; Eaton WL; Perry MC; Carey RW; Frei EF; Green MR
N Engl J Med; 1990 Oct; 323(14):940-5. PubMed ID: 2169587
[TBL] [Abstract][Full Text] [Related]
17. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
[TBL] [Abstract][Full Text] [Related]
18. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
Isobe T; Fukuoka M; Negoro S; Sugiura T; Kawahara M; Kudoh S; Araki J; Nakagawa K; Yokozaki M; Yamakido M; Ariyoshi Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1091-6. PubMed ID: 10945001
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
[TBL] [Abstract][Full Text] [Related]
20. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
